A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma.
about
Treatment of relapsed and refractory multiple myelomaEvolving paradigms in the treatment of relapsed/refractory multiple myeloma: increased options and increased complexityEvolving Paradigms in the Management of Multiple Myeloma: Novel Agents and Targeted TherapiesPomalidomide for the treatment of relapsed-refractory multiple myeloma: a review of biological and clinical data.Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma.Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study.A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myelomaPhase 1 dose-escalation study of IV ixazomib, an investigational proteasome inhibitor, in patients with relapsed/refractory lymphoma.Clinical outcome of bortezomib retreatment in patients with relapsed or refractory multiple myeloma.A phase I study of vorinostat combined with bortezomib in Japanese patients with relapsed or refractory multiple myeloma.Antileukemic activity and mechanism of drug resistance to the marine Salinispora tropica proteasome inhibitor salinosporamide A (Marizomib).Acetyl-L-carnitine (ALCAR) for the prevention of chemotherapy-induced peripheral neuropathy in patients with relapsed or refractory multiple myeloma treated with bortezomib, doxorubicin and low-dose dexamethasone: a study from the Wisconsin OncologyReversal of bortezomib resistance in myelodysplastic syndrome cells by MAPK inhibitors.Estimating the Costs of Therapy in Patients with Relapsed and/or Refractory Multiple Myeloma: A Model Framework.Drug rechallenge and treatment beyond progression--implications for drug resistance.Ibrutinib inhibits BTK-driven NF-κB p65 activity to overcome bortezomib-resistance in multiple myeloma.Velcade (Bortezomib) Receives 2 New FDA Indications: For Retreatment of Patients with Multiple Myeloma and for First-Line Treatment of Patients with Mantle-Cell LymphomaMultiple myeloma in the marrow: pathogenesis and treatments.CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma.Farydak (Panobinostat): First HDAC Inhibitor Approved for Patients with Relapsed Multiple MyelomaPotential role of exosome-associated microRNA panels and in vivo environment to predict drug resistance for patients with multiple myeloma.Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR studyInternational Myeloma Working Group recommendations for global myeloma care.Current strategies for treatment of relapsed/refractory multiple myeloma.Harnessing system models of cell death signalling for cytotoxic chemotherapy: towards personalised medicine approaches?Treatment-related symptom management in patients with multiple myeloma: a review.Retreatment and Prolonged Therapy with Subcutaneous Bortezomib in Patients with Relapsed Multiple Myeloma: A Randomized, Controlled, Phase III Study.Long-term disease control in a refractory multiple myeloma patient treated with bortezomib mono-therapy: a case report and review of literature.TrxR1 inhibition overcomes both hypoxia-induced and acquired bortezomib resistance in multiple myeloma through NF-кβ inhibition.Epigenetic mechanisms of cell adhesion-mediated drug resistance in multiple myeloma.Outcomes of multiple myeloma patients receiving bortezomib, lenalidomide, and carfilzomib.Real-world treatment patterns and associated progression-free survival in relapsed/refractory multiple myeloma among US community oncology practices.Prediction of patients with multiple myeloma eligible for second- or third-line treatment in France.Salvage therapy in first relapse: a retrospective study in a large patient population with multiple myeloma.Reduced frequency treatment with bortezomib plus dexamethasone for elderly patients with relapsed and/or refractory multiple myeloma: a phase 2 study of the Japanese Myeloma Study Group (JMSG-0902).Efficacy and safety of bortezomib-based retreatment at the first relapse in multiple myeloma patients: A retrospective study.Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone vs. placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1.Frontline bortezomib and rituximab for the treatment of newly diagnosed high tumour burden indolent non-Hodgkin lymphoma: a multicentre phase II study.Safety of BTZ retreatment for patients with low-grade peripheral neuropathy during the initial treatment.Integration of Novel Agents into the Care of Patients with Multiple Myeloma.
P2860
Q26749180-77332F8B-06B1-43CB-8F22-F78258E24B10Q26771331-06991F4B-845F-4437-AD32-F467C021F40BQ27026478-F7182C2E-8DB5-4942-BD6F-24EDBE847AC5Q30802505-2683517B-C7E1-4CE2-9A17-92D2DD1AFBF0Q33411440-F8749188-8D6A-43E7-8EBF-8B0D5F67A26AQ33411708-6D2ABCF8-9495-4C48-905A-73285EC998C6Q33412684-EE9541A0-0A04-4661-ADA5-E5D56AD74825Q33418257-36EC566A-64FE-4FB7-AC42-9A6845F26A82Q33419442-C72CCCB1-25A7-4DCF-AF14-7B83969E4C58Q33427979-BD45372B-4DD6-4784-BCD8-1FF476502A24Q33742779-8C42A8C0-7C86-4017-BBA5-EDE4203DB3A5Q34245549-DF50400D-6FFF-497D-8955-B8D93246AB9DQ35114769-17F6D0FC-4108-468D-9885-804FC7E331A0Q35809982-63EBE4D7-E70A-4C4E-9BEF-13A29CD12D7AQ35967416-719BB1DD-52B9-4BCF-9B38-4732651C97A4Q36183770-BEB9BD06-90D4-4F7E-B2D1-C48B1C5DD34AQ36333791-C1B6C0E2-9805-4113-ABC2-961E33AE1821Q36725401-6E15F194-18E4-4296-889A-588F360C239DQ37058114-2B88C66F-61FA-41E0-B005-654370C00AF1Q37237713-4867709C-71F7-49E3-BA0F-E0D98E49268EQ37327618-9CE01193-58D7-4FE1-94DF-7392502A481EQ37570630-E1497095-8BA2-4C7A-9607-03EB4B8963EBQ38157532-628AC15D-B120-411B-B012-BD413DC00EA8Q38182683-5C9344C0-5CB3-42A2-928F-C783C715607CQ38183302-EBBFF609-EE28-4025-89CD-62A0D7EFB2F9Q38342281-07374107-CB66-4F1F-94A9-0256AC7F8829Q38372319-84AEA150-ADF6-4567-B16F-06BB84B61F08Q38697604-183C21E7-4D29-48E5-AA25-1017424AA329Q38805723-86C3F473-279C-49A3-9B89-E8DAFEAEF06BQ38895512-D0F707F6-6629-43D0-936C-9186F035E83FQ39117277-9FF6B15A-87FB-4861-BB2F-FEFE76ED85CAQ39690253-1E53B413-A1F9-4526-8CDE-DCF95186A3CEQ39778109-BC39D8EB-7507-4697-A963-8A129406B728Q40454277-62FA3627-36FD-4A7C-A6C3-A57F6F2E4FB5Q40818284-991BC2D5-ABDA-4D07-B9CB-E3CCD9FC8E69Q41705410-93FE2CD4-C272-4370-9A67-07162A5177ABQ42181641-3169C603-45B6-4EEC-A2FA-1E1575CECCD4Q46130238-C6ADC9A2-3F47-4295-8604-2E8CE083C25DQ46577984-3A26FBC4-C4CC-48CE-9E92-990FD22500DFQ46754093-F361A6B7-149B-4C0E-8271-FBBBCE7CF241
P2860
A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma.
description
2013 nî lūn-bûn
@nan
2013 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
A prospective, international p ...... ith relapsed multiple myeloma.
@ast
A prospective, international p ...... ith relapsed multiple myeloma.
@en
type
label
A prospective, international p ...... ith relapsed multiple myeloma.
@ast
A prospective, international p ...... ith relapsed multiple myeloma.
@en
prefLabel
A prospective, international p ...... ith relapsed multiple myeloma.
@ast
A prospective, international p ...... ith relapsed multiple myeloma.
@en
P2093
P2860
P356
P1476
A prospective, international p ...... ith relapsed multiple myeloma.
@en
P2093
Adriana Teixeira
Esther Broer
Igor W Blau
Joan Bladé
Johannes Drach
Maria T Petrucci
Nathalie Allietta
Pilar Giraldo
Ralf Angermund
Vivien Mitchell
P2860
P304
P356
10.1111/BJH.12198
P407
P577
2013-01-07T00:00:00Z